The partnership is aiming to collect and analyse digital biomarkers to identify signs of response and relapse in Beckley’s upcoming 5-MeO-DMT Phase 2 clinical trials.
A new study has revealed how ketamine works, which scientists say paves the way toward the development of safe, effective treatments for depression.
Cybin has confirmed it has received approval for its Phase 1/2a trial evaluating its proprietary deuterated psilocybin analogue for the treatment of Major Depressive Disorder (MDD).
Christie’s is presenting its Non-Fungible Token (NFT) auction – ‘Cartography of the Mind’ – to raise funds for the Multidisciplinary Association for Psychedelic Studies (MAPS).
The first patient has been dosed in HMNC and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study.
A new study from Northwestern Medicine has identified for the first time how ketamine works so quickly, and how it might be adapted for use as...
Awakn Life Sciences will be carrying out a follow-on behavioural study to focus on gambling disorder following its recent successful pilot study and patent filing.
Biopharma firm Ceruvia Lifesciences is to carry out a clinical trial of synthetic psilocybin as a potential treatment for obsessive-compulsive disorder (OCD).
Awakn Life Sciences has filed a Patent Cooperation Treaty (PCT) application for the treatment of behavioural addictions with ketamine and ketamine-assisted psychotherapy.
Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone...
The University of California, Davis (UC Davis) and the University of Colorado Anschutz Medical Campus have received a $2.7m (~£2.15m) grant from the National Institute on...
Dr Laura Trespidi is joining the Beckley Psytech leadership team as CDO, bringing more than 30 years’ experience in global pharmaceutical and biotechnology companies.
